BioCentury | Oct 23, 2020
Emerging Company Profile

Be Bio: bringing the B to cell therapy

Be Biopharma launched Thursday with a $52 million series A round led by Atlas Venture and RA Capital and a platform to engineer B cells that could overcome the durability, safety and re-dosing challenges of existing cell...
BioCentury | Sep 26, 2020
Product Development

Merck’s myeloid data add support for the emerging target class

The myeloid cell targets that have been generating preclinical attention are moving into the clinical arena, and the first look at data from Merck’s ILT4 program provides an early signal that the strategy...
BioCentury | Sep 5, 2020
Translation in Brief

Matt Disney’s microRNA-targeting angiogenesis compound; Arrakis’ platform to find compounds’ RNA targets; dual target CAR Ts for HIV and more

Scripps microRNA-targeted VEGF-A stimulatorA Scripps Research Institute team led by Matthew Disney has designed a compound that targets a  precursor of miR-377, a direct inhibitor of angiogenesis...
BioCentury | Aug 27, 2020
Distillery Therapeutics

Targeting CXCR3, CXCL9 for osteoporosis

DISEASE CATEGORY: Musculoskeletal INDICATION: Osteoporosis Inhibiting the chemokine receptor CXCR3 or its ligand CXCL9 could treat osteoporosis. In a medaka fish model of RANKL-induced osteoporosis, two CXCR3 inhibitor tool compounds reduced mineralization defects including resorption...
BioCentury | Aug 22, 2020
Emerging Company Profile

Luminary: turning cell engineering tools into therapies

Luminary is parlaying its founders’ experience in non-viral genome engineering to build a pipeline of cell therapies that are faster to develop and more cost-effective than those that depend on virus-based...
BioCentury | Jul 18, 2020
Translation in Brief

Fate licenses rejection-resistant T cell therapies; plus a marker for anti-PD-1 treatment responsiveness, a cell proliferation control switch and more

Baylor’s engineered T cells designed to avoid immune rejection Baylor College of Medicine has granted Fate Therapeutics Inc. (NASDAQ:FATE) an exclusive license to alloimmune defense receptors, which render allogeneic cell therapies resistant to host immune...
BioCentury | Jul 7, 2020

July 7 Quick Takes: Luminary-Case Western partner on BLyS-targeting CAR T; plus Dragonfly-BMS, HiberCell-Biothera and Biogen-Mass Eye and Ear

Luminary, Case Western partner on CAR T against BLyS Minneapolis-based Luminary Therapeutics Inc. gained an option from Case Western Reserve University to exclusively license a novel BLyS target for use in CAR T constructs; financial...
BioCentury | Jun 19, 2020

In second innovative deal this month, AbbVie gains option to Alpine’s ‘first-in-class’ lupus program

AbbVie’s deal with Alpine on Thursday is its second innovative partnership in as many weeks, giving the company an option to a Phase II-ready therapy for lupus, a disease that has seen only one targeted...
BioCentury | Jun 4, 2020
Product Development

With impending Benlysta submission, GSK seeking new paradigm in lupus nephritis treatment

Newly presented Phase III data burnish GSK’s case for a regulatory submission planned for this month seeking to expand the label of lupus drug Benlysta to include lupus nephritis. Richard Furie, the lead investigator of...
BioCentury | Jun 2, 2020

Personalized kidney play Chinook rounds out pipeline, lands on NASDAQ via Aduro deal

By uniting with publicly traded Aduro, Versant Ventures-incubated kidney company Chinook will gain a clinical asset for IgA nephropathy while also delivering liquidity to a VC syndicate that is committing additional capital to fund the...
Items per page:
1 - 10 of 363